103 related articles for article (PubMed ID: 22203757)
1. Artificial prostate-specific antigen persistence after radical prostatectomy.
Poyet C; Hof D; Sulser T; Müntener M
J Clin Oncol; 2012 Feb; 30(5):e62-3. PubMed ID: 22203757
[No Abstract] [Full Text] [Related]
2. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
3. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
Morgan BR; Tarter TH
J Urol; 2001 Dec; 166(6):2311-2. PubMed ID: 11696766
[TBL] [Abstract][Full Text] [Related]
4. Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies.
Park S; Wians FH; Cadeddu JA
Int J Urol; 2007 Mar; 14(3):251-3. PubMed ID: 17430267
[TBL] [Abstract][Full Text] [Related]
5. [False Elevation of Prostate-Specific Antigen Caused by Heterophilic Antibody Interference after Radical Prostatectomy : A Case Report].
Kamiyama Y; Somiya S; Fujikawa S; Yamada Y; Tamaki M; Kanaoka T; Hayashi T
Hinyokika Kiyo; 2017 Oct; 63(10):435-437. PubMed ID: 29103259
[TBL] [Abstract][Full Text] [Related]
6. Benign positive margins after radical prostatectomy means a poor prognosis--pro.
Djavan B; Milani S; Fong YK
Urology; 2005 Feb; 65(2):218-20. PubMed ID: 15708025
[No Abstract] [Full Text] [Related]
7. Benign positive margins after radical prostatectomy means a poor prognosis--con.
Rubin MA; Montie JE
Urology; 2005 Feb; 65(2):221-3. PubMed ID: 15708026
[No Abstract] [Full Text] [Related]
8. Incorrect biochemistry complicates prostate cancer management.
McAuley I; Steinhoff G; McNeely M; Blood P
Can J Urol; 2002 Apr; 9(2):1496-7. PubMed ID: 12010595
[TBL] [Abstract][Full Text] [Related]
9. Characterization of minute adenocarcinomas of prostate at radical prostatectomy.
Truskinovsky AM; Sanderson H; Epstein JI
Urology; 2004 Oct; 64(4):733-7. PubMed ID: 15491711
[TBL] [Abstract][Full Text] [Related]
10. The value of prostate-specific antigen in the management of localized prostatic cancer.
Walsh PC; Oesterling JE; Epstein JI; Bruzek DJ; Rock RC; Chan DW
Prog Clin Biol Res; 1989; 303():27-33. PubMed ID: 2476820
[TBL] [Abstract][Full Text] [Related]
11. 3.0T MR-guided laser ablation of a prostate cancer recurrence in the postsurgical prostate bed.
Woodrum DA; Mynderse LA; Gorny KR; Amrami KK; McNichols RJ; Callstrom MR
J Vasc Interv Radiol; 2011 Jul; 22(7):929-34. PubMed ID: 21708319
[TBL] [Abstract][Full Text] [Related]
12. [Case of persistent false elevation of prostate-specific antigen after radical prostatectomy].
Shida Y; Imasato Y; Tsurusaki T; Kusaba Y
Hinyokika Kiyo; 2010 Apr; 56(4):233-5. PubMed ID: 20448449
[TBL] [Abstract][Full Text] [Related]
13. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
14. [Prostate-specific antigen. A new biological serum marker for prostatic adenocarcinoma].
Haukaas S; Skaarland E; Halvorsen OJ; Stensland E; Farstad M
Tidsskr Nor Laegeforen; 1990 Sep; 110(23):2990-3. PubMed ID: 1700496
[TBL] [Abstract][Full Text] [Related]
15. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
[TBL] [Abstract][Full Text] [Related]
16. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
[TBL] [Abstract][Full Text] [Related]
17. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
18. Undetectable ultrasensitive PSA after radical prostatectomy for prostate cancer predicts relapse-free survival.
Doherty AP; Bower M; Smith GL; Miano R; Mannion EM; Mitchell H; Christmas TJ
Br J Cancer; 2000 Dec; 83(11):1432-6. PubMed ID: 11076649
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of positive surgical margins in robotic-assisted radical prostatectomy, open retropubic radical prostatectomy, and laparoscopic radical prostatectomy: a comparative histopathologic study from a single academic center.
Albadine R; Hyndman ME; Chaux A; Jeong JY; Saab S; Tavora F; Epstein JI; Gonzalgo ML; Pavlovich CP; Netto GJ
Hum Pathol; 2012 Feb; 43(2):254-60. PubMed ID: 21820147
[TBL] [Abstract][Full Text] [Related]
20. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
